TY  - BOOK
AU  - Attaran, Saina
AU  - Buchanan, Kyle
AU  - Gajanana, Deepakraj
AU  - Garcia-Garcia, Hector M
AU  - Iantorno, Micaela
AU  - Rogers, Toby
AU  - Torguson, Rebecca
AU  - Waksman, Ron
AU  - Weintraub, William S
TI  - Genetic and Nongenetic Implications of Racial Variation in Response to Antiplatelet Therapy. [Review]
SN  - 0002-9149
PY  - 2019///
KW  - *Continental Population Groups
KW  - *Coronary Artery Disease/dt [Drug Therapy]
KW  - *Coronary Artery Disease/ge [Genetics]
KW  - *Platelet Aggregation Inhibitors/tu [Therapeutic Use]
KW  - Genotype
KW  - Humans
KW  - Phenotype
KW  - Treatment Outcome
KW  - MedStar Heart & Vascular Institute
KW  - Journal Article
KW  - Review
N1  - Available online from MWHC library: 1995 - present, Available in print through MWHC library: 1999 - 2006
N2  - Copyright (c) 2019 Elsevier Inc. All rights reserved; Race has been identified as an independent risk factor for poor prognosis and an independent predictor of survival in coronary artery disease. Race-related dissimilarities have been identified in cardiovascular patients in terms of age of presentation, co-morbidities, socioeconomic status, and treatment approach as well as genetically driven race-related disparities in responsiveness to medications. Antiplatelet therapy represents a fundamental component of therapy in cardiovascular patients, especially in patients presenting with acute coronary syndromes. It has been argued that the different level of platelet reactivity and varying response to antiplatelet therapy among races may account in part for worse outcomes in certain populations. The purpose of this review is to describe genotypic and phenotypic race-related differences in platelet reactivity and responsiveness to cardiovascular treatment, focusing on antiplatelet therapy to highlight the need establish a more effective and targeted antithrombotic strategy
UR  - https://dx.doi.org/10.1016/j.amjcard.2019.02.047
ER  -